# Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

Source: https://onco.cc/trials/nct07140679/  
OnCo record `nct07140679` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of toripalimab in colorectal cancer, run by Emory University, now recruiting.

## Summary

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer is a phase 2, interventional study registered as NCT07140679 by Emory University, with a registry enrolment figure of 40 participants, started 2025-09-19 and due to reach its primary completion in 2029-09-30. Interventions recorded: Biopsy Procedure; Biospecimen Collection; Colonoscopy; Computed Tomography; Questionnaire Administration; Toripalimab. Conditions listed: Localized Colon Carcinoma; Stage IIB Colon Cancer AJCC v8; Stage IIC Colon Cancer AJCC v8; Stage III Colon Cancer AJCC v8. Primary outcome: 3-year Disease free survival (DFS). Colorectal eligibility wording from the registry: "* Patients with resected pathologic stage IIB, IIC and III dMMR colon cancer (American Joint Committee on Cancer \[AJCC\] 8)". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07140679
- Phase: 2
- Setting: A Phase II Trial of Adjuvant Toripalimab in High Risk Localized Colon Cancer With Mismatch Repair Deficiency
- Sponsor: Emory University
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07140679: https://clinicaltrials.gov/study/NCT07140679

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Toripalimab](https://onco.cc/drugs/toripalimab/)
- companies: [Coherus BioSciences](https://onco.cc/companies/coherus/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07140679.json